

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**LOK SABHA
UNSTARRED QUESTION NO. 3393
TO BE ANSWERED ON 5TH AUGUST, 2016**

HEPATITIS C

3393. SHRI PONGULETI SRINIVASA REDDY:

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) whether the Government has taken cognizance of the increasing number of patients affected by Hepatitis C in the country especially in Telugu States and there is no vaccination, if so, the details of number of cases reported/treated and patient died, State/UT-wise;
- (b) whether safe and efficacious and direct-acting antiviral drugs against Hepatitis C are available in the country, if so, the details thereof;
- (c) whether the Government has taken preventive measures to make available and affordable these drugs/treatment to the low income/poor people of the country in the Hepatitis C prevailing areas; and
- (d) if so, the details thereof and if not, the reasons therefor?

**ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND
FAMILY WELFARE
(SMT. ANUPRIYA PATEL)**

(a): The Government is aware of the fact that the incidence of hepatitis 'C' is increasing in the country. However, since health is a state subject, the details of cases reported/treated and death of patients is not maintained centrally. Currently, no vaccine is available for hepatitis 'C'.

(b) to (d): CDSCO has approved many antiviral drugs like Lamivudine, Adefovir Dipivoxil, Entecavir, Telbivudine, Tenofovir, Sofosbuvir, FDC of Ledipasvir and Sofosbuvir, Daclatasvir, etc., for treatment of various Hepatitis infections in the country. Further, a number of Indian companies have also entered into an arrangement with a multinational company to manufacture generic version of hepatitis 'C' medicine 'Sofosbuvir'. The Indian generic manufacturers will have the right to develop and market generic version in India and a few other countries.